PDCD1 and cancer: Immune checkpoint inhibitors, including those targeting the programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) pathway, have revolutionized the treatment approach of many cancers, including non-small cell lung cancer (NSCLC).